Abstract
Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
CNS & Neurological Disorders - Drug Targets
Title:Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior
Volume: 12 Issue: 7
Author(s): Maurizio Pompili, Gianluca Serafini, Mario Palermo, Maria Elena Seretti, Henry Stefani, Gloria Angeletti, David Lester, Mario Amore and Paolo Girardi
Affiliation:
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
Abstract: Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Export Options
About this article
Cite this article as:
Pompili Maurizio, Serafini Gianluca, Palermo Mario, Seretti Elena Maria, Stefani Henry, Angeletti Gloria, Lester David, Amore Mario and Girardi Paolo, Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior, CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990098
DOI https://dx.doi.org/10.2174/18715273113129990098 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of IL-15 Signaling in the Induction of Innate Antiviral Responses
Current Signal Transduction Therapy Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design MicroRNA Dysregulation in Gastric Cancer
Current Pharmaceutical Design Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
Current Neuropharmacology Progress in COX-2 Inhibitors: A Journey So Far
Current Medicinal Chemistry Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design Carbocyclic Nucleosides (Carbanucleosides) as New Therapeutic Leads
Current Topics in Medicinal Chemistry Microarray Studies in Understanding the Mechanism of Action of Antiepileptic Drugs
Current Psychopharmacology The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus
Current Signal Transduction Therapy Gene Expression Analysis for High Throughput Screening Applications
Combinatorial Chemistry & High Throughput Screening Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Immunomodulatory Therapy Associated to Anti-Parasite Drugs as a Way to Prevent Severe Forms of Malaria
Current Clinical Pharmacology Biosynthetic Pathways of Bioactive N-Acylethanolamines in Brain
CNS & Neurological Disorders - Drug Targets Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research